Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Maprotiline”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 127 records · Page 7Linked to original sources
PubMed1975

Double-bind comparison of maprotiline with amitriptyline in the treatment of depressive illness.

Thirty patients closely matched for age, sex and duration of illness were treated with either amitriptyline or maprotiline in a double-blind, between-patient trial. Within limits of the small number of patients in the trial, maprotiline produced a significantly quicker improvement during the first 2 weeks as judged by the scores on the Hamilton Rating Scale. Maprotiline showed better tolerability than amitriptyline overall, especially as far as trial drop-out rates were concerned.

Adult↗
PubMed1976

Antidepressant treatment with maprotiline in the management of emotional disturbances in patients with acute myocardial infarction: a controlled study.

In coronary artery disease the patients usually manifest both anxiety and depression disturbances. A controlled clinical study was conducted to test the efficacy of a new antidepressant agent, maprotiline, in the early stages of acute myocardial infarction. The sample consisted of 126 patients, sixty-three receiving orally 25 mg of maprotiline twice daily and the remainder 5 mg of diazepam twice daily. Treatment lasted on an average two weeks (ten days to eight weeks). The depressive and/or anxiety conditions were rated on the basis of a questionnaire administered before and after treatment. Depression improved markedly in patients receiving maprotiline, while the two drugs developed a comparable anxiolytic action. Tolerability was good. No clinical or ECG evidence of cardiotoxic signs was detected. The importance of a drug with these characteristics in the management of emotional disturbances in the early stages of coronary artery disease is emphasized.

Acute Disease↗
PubMed1979

Neurobiochemical aspects of maprotiline (Ludiomil) action.

In the first part of the paper a short review of the neurobiochemical effects of the antidepressant drug maprotiline is given. Its most obvious effect is the inhibition of noradrenaline uptake in peripheral and central neurones. The peculiarity of this action consists in its high degree of selectivity, as no inhibition of serotonin uptake could be demonstrated in vivo. In the second part, the results of new experiments are described. These show that serotonin uptake is not diminished in rat mid-brain synaptosomes even after treatment with very high doses of maprotiline (600 mg/kg p.o.). In addition, the influence of the antidepressant on noradrenaline and serotnin uptake was studied in rat cerebral cortex, cerebellum, hypothalamus and pons-medulla. Dopamine and serotonin uptake were measured in the corpus striatum. Again, only the uptake of noradrenaline was found to be inhibited. There was not even a slight tendency towards inhibition of serotonin uptake. This high degree of selectivity distinguishes maprotiline from the tricyclic antidepressants and thus makes it an intersting 'extreme-type' uptake inhibitor.

Animals↗
PubMed1983

Intravenous maprotiline in severe and resistant primary depression: a double-blind comparison with clomipramine.

A double-blind, randomized trial is described which was designed to compare the clinical effect of 100 mg daily of maprotiline (Ludiomil) and of clomipramine (Anafranil) given by the intravenous route in forty hospitalized female patients with severe and resistant primary depression. Physicians' assessment of patients' progress was made following 5, 9 and 21 days of treatment. The response rates to maprotiline and clomipramine were not significantly different even if a greater number of patients responded to clomipramine. None of the demographic and clinical variables considered could be identified as factor predicting the response to maprotiline and to clomipramine, even if a trend for a preferential responsiveness to clomipramine in the older patients was observed.

Adolescent↗
PubMed1983

Seizures associated with high maprotiline serum concentrations.

Maprotiline is a tetracyclic antidepressant which appears to have accounted for a relatively large proportion of the seizures associated with antidepressant use. The literature proposes two mechanisms of seizure induction: interaction with other medications and concomitant medical conditions lowering the seizure threshold. Observations during a study of maprotiline blood levels suggest that elevated serum concentrations achieved with therapeutic doses may also be linked to the seizure-induction mechanism. Monitoring of maprotiline blood levels may help to identify patients at risk.

Adult↗
PubMed1975

A controlled trial of maprotiline (Ludiomil) in depressed outpatients.

A double blind comparison is reported of a new tetracyclic antidepressant, maprotiline, with amitriptyline and placebo in psychiatric outpatients. Amitriptyline was significantly more effective than placebo in its global effect on depression. Maprotiline emerged as neither inferior to amitriptyline nor superior to placebo. Methodological difficulties prevented an adequate assessment of the anxiolytic activity of maprotiline.

Adult↗
PubMed1975

A controlled study of a tetracyclic antidepressant--maprotiline (Ludiomil).

Maprotiline (Ludiomil) is a dibenzo bicyclooctadiene pharmacologically related to the tricyclic antidepressants and stereochemically having a tetracyclic structure. A controlled, double-blind comparison of maprotiline and imipramine in a group of 71 female outpatients with primary depression is presented. Maprotiline was found to be at least as effective as imipramine and significantly better in depressive neurosis. It also showed a bipolar action, being effective in both agitation and retardation.

Adjustment Disorders↗
PubMed1975

[Cardiopulmonary effects after i.v. administration of maprotiline in the dog].

The cardiopulmonary effects of the antidepressive agent maprotiline were investigated in the dog. In ventilation experiments on dogs anaesthetized with chloralose, respiratory minute volume decreased by 5-10% shortly after intravenous injection of 1 and 3 mg/kg; acid-base-balance variables remained unchanged. After an intravenous dose of 10 mg/kg ineffective hyperventilation was observed, associated with a transient decrease of P-O2 and a slight increase in P-CO2 in the arterial blood. In cardiac-catheterization experiments on dogs anaesthetized with chloralose and morphine and receiving artificial respiration, an intravenous dose of 3 mg/kg maprotiline had no appreciable effect on the cardiovascular system, apart from a transient and slight, but statistically significant increase in pulmonary capillary pressure immediately after the injection. Anaesthesia was slightly deeper and more prolonged after the intravenous administration of maprotiline.

Animals↗
PubMedDate not supplied

Acute effects of maprotiline, doxepin and zimeldine with alcohol in healthy volunteers.

In a double-blind and cross-over trial, 12 healthy volunteers received single oral doses of maprotiline 75 mg, doxepin 25 mg, zimeldine 200 mg and placebo, alone and with alcohol (1 g/kg), at one-week intervals. Objective tests of performance (tracking, choice reaction, flicker fusion, body sway, nystagmus, Maddox wing) and ratings of subjective feelings were done before the drug intake (baseline) and 1 1/2, 3, 4 1/2, 6 and 7 1/2 hr after it. Maprotiline and doxepin proved subjectively sedative, whilst doxepin and zimeldine prolonged choice reaction time. An increase of alcohol effects was seen clearly after doxepin, to lesser extent after maprotiline and not at all after zimeldine. On the contrary, zimeldine antagonized alcohol-induced impairment in the tracking test.

Adult↗
PubMed1977

A comparison of maprotiline (Ludiomil) and amitriptyline (2).

Seventy-five patients were admitted to a double-blind multicentre trial of maprotiline (Ludiomil) and amitriptyline in the management of depression in general practice. Forty-seven patients, twenty-one on maprotiline and twenty-six on amitriptyline completed the study. Statistical analysis of admission data showed that the groups were not strictly comparable in that the maprotiline group contained many more males and had a greater average age. Nevertheless, although there was a suggestion that amitriptyline was faster-acting in the younger age group that received it, there were no statistically significant differences between the two treatment groups as regards onset of effect, clinical efficacy or tolerability.

Adult↗
PubMed1985

Treatment of depression in outpatients: a controlled comparison of the onset of action of amoxapine and maprotiline.

In a 4-week double-blind study, amoxapine and maprotiline were compared in the treatment of 76 outpatients with moderate to severe depressive illness. Mean maximum daily dosages were 230 mg for amoxapine and 165 mg for maprotiline. The data suggest that in these dosages amoxapine and maprotiline are equally effective overall. However, significant differences favored amoxapine at Days 4 and 7, in agreement with other studies showing early onset of therapeutic action of amoxapine.

Adult↗
PubMed1984

Multicenter evaluation of maprotiline hydrochloride for treatment of depression.

Maprotiline hydrochloride tablets were given to 266 patients with either a dysthymic disorder or a major depressive disorder. The mean starting dosage was 70.2 mg/day in patients younger than 60 years of age and 68.6 mg/day in those aged 60 years and over. For patients completing at least four weeks of treatment, the mean final dosage was 127.6 mg/day in younger patients and 100.0 mg/day in geriatric patients. Follow-up evaluations of response and adverse effects were made at each of the following intervals after the start of therapy: one week, two to three weeks, four to five weeks, and six weeks or more. Assessment of response was based on the physicians' evaluations of overall improvement and improvement in sleep pattern, anxiety level, mood, and drive. Eighteen patients never returned and were excluded from all assessments. The remaining patients were evaluated for observations recorded within the foregoing time intervals. A rapid onset of action was evident in the fact that 73% of evaluated patients had at least a minimal response after one week of treatment, and after six weeks 76% had achieved moderate or marked improvement in their overall condition. Patients' sleeping patterns showed the most rapid and dramatic response, with 59% of evaluated patients improved after one week and 90% after six weeks of maprotiline. Anxiety decreased in 57% of patients after one week and in 81% after six weeks. Depression was reduced in 46% of evaluated patients after one week and in 86% after six weeks. Forty-one percent of patients exhibited more drive after one week of maprotiline and 78% did so after six weeks.(ABSTRACT TRUNCATED AT 250 WORDS)

Adolescent↗
PubMed1983

Determination of the antidepressants maprotiline and amoxapine, and their metabolites, in plasma by liquid chromatography.

Maprotiline, amoxapine, and their metabolites were determined in plasma by three separate procedures, each of which involves a three-step extraction followed by reversed-phase separations. Amoxapine, maprotiline, and N-desmethylmaprotiline can be measured with use of a conventional C-18 column with 10% carbon load, but analyses for 7- and 8-hydroxyamoxapines require a small (5-microns) particle size, high carbon load, 20% C-18 column with 0.2 mol/L phosphate as mobile phase. Within-run and day-to-day CVs were 5% and 8%, respectively. Peak-height ratios were linearly correlated with concentrations between 0 and 400 micrograms/L. Detection limits ranged from 1 to 3 ng. Interference studies indicated that nortriptyline co-elutes with maprotiline. Assays of patients' plasma showed substantial amounts of these drugs and most of their metabolites, but only trace amounts of 7-hydroxyamoxapine.

Amoxapine↗
PubMed1982

To the pharmacological profile of maprotiline.

Experimental EEG study of sleep-vigil cycles in rats with implanted brain electrodes showed that maprotiline has lower inhibitory effects on the REM sleep, sleep onset and mean duration of sleep cycles than imipramine. Maprotiline reveals significantly lower cardiotoxicity than imipramine and amitriptyline in the test on chick embryo heart. Embryotoxicity risk, evaluated on chick embryo by the method CHEST is significantly lower in maprotiline than in imipramine, nortriptyline and amitriptyline.

Abnormalities, Drug-Induced↗
PubMed1982

Clinical experience with maprotilin and maprotilin/clomipramine infusions in resistant depression.

Maprotilin was given orally to 34 depressive patients for 3-6 weeks, or in daily morning i. v. infusions for 10-15 days to 23 patients, and in combined infusions with clomipramine to 32 patients. - At oral administration the effect was evident only after 10 days of treatment; most depressive symptoms improved. Maprotilin in infusions had a rapid onset of effect, being especially intensive on depressive mood and anxiety. The combined infusions of maprotilin and clomipramine affected an even wider range of symptoms. The factor anxiety somatization decreased significantly already after 7 days of treatment, more expressively after combined infusions. Side effects occurred only during the infusions.

Administration, Oral↗
PubMed1993

Predicting therapeutic results with levoprotiline and maprotiline in major depression: the role of the outcome criteria.

We describe a double-blind study involving 58 in-patients with major depression (DSM-III). After one week on placebo, the patients were randomly assigned to either levoprotiline or maprotiline treatment for three weeks. In the next three weeks, responders were maintained on the same medication and non-responders were shifted to treatment with the complementary drug. After the initial three weeks' treatment, 31% of levoprotiline patients and 58% of maprotiline patients had responded. Both in the initial three-week period and after shifting non-responders to the complementary drug, there were significant differences in favour of maprotiline. The comparison of properties of different outcome criteria in prediction analyses shows that the final score gives the best agreement with global evaluation; using the delta score (final minus baseline) or ratio score (final/baseline) as the outcome criterion may yield paradoxical results.

Adult↗
PubMed1993

Dynamics of the effects of levoprotiline and maprotiline on EEG in patients with major depressive episodes (DSM-III-R).

The presented study compares the effect of the well-tested antidepressant maprotiline and a new antidepressant with an atypical pharmacological profile, levoprotiline, on EEG during repeated assessment after single dose administration. From the original number of 34 patients fulfilling the criteria of a major depressive episode (DSM-III-R) on account of a low-voltage record or pathological findings 11 were eliminated. To 12 of the remaining patients levoprotiline was administered and to 11 maprotiline, after a one-week placebo period, in doses of 150 mg. The EEG was recorded after an accommodation session immediately before, 1.5, 3, 4.5, 6 and 24 hours after a single dose administration. The record was taken on a 16-channel average reference montage at rest with closed eyes. Two-minute intervals were divided into 30 four-second periods at a sampling frequency of 128 Hz. From the signal by means of FFT the spectra were estimated and the mean spectrum for the entire recording was calculated. This was then divided into 10 frequency bands. The new method of frequency analysis of alpha-entropy was also used which is a global measure of the difference between two spectra. Three hours after administration of a single dose levoprotiline had an EEG profile corresponding to the profile of tricyclic antidepressants, i.e. it increased the values of the power spectra density in the region of 5-8.5 Hz and in the entire beta band; the decline of power in the alpha band was, however, absent. As regards maprotiline, 3 hours after administration a profile typical for antidepressants was not found; obviously because of the great variance of values of power spectra density as a result of great interindividual differences in the ingestion phase. Changes of the EEG spectrum expressed as values of alpha-entropy during different periods of apparently assessment are not incidental. After the initial rise of values a decline occurs.

Adult↗
PubMed1996

Different effects of the antidepressant drugs imipramine, maprotiline and bupropion on insulin secretion from mouse pancreatic islets.

In some previous studies, acute administration of some antidepressants has been reported to cause significant changes in the levels of blood glucose and insulin in the rabbit. In the present study the effects of several antidepressants representing classical groups of antidepressants, namely imipramine (CAS 50-49-7, I), maprotiline (CAS 10347-81-6, M) and bupropion (CAS 34911-55-2, (B) on insulin secretion from the isolated islets of Langerhans in mice was studied. Maprotiline and bupropion stimulated insulin release, while imipramine was without any effect in presence of 8.3 mmol/l glucose. On the other hand, in presence of 16.7 mmol/l imipramine and maprotiline suppressed the stimulated insulin secretion. Bupropion inversely significantly stimulated the insulin secretion in presence of 16.7 mmol/l glucose. It is concluded that the changes of blood glucose and plasma insulin observed in vivo may at least in part be due to respective changes of insulin secretion. The treatment of diabetic patients receiving antidepressant drugs with hypoglycaemic agents should be taken in consideration.

Animals↗